GLP-1 works best with structure. This is the structure.
A structured group program for patients on GLP-1 therapy and those pursuing metabolic optimization — combining physician oversight, nutritionist coaching, and behavioral science.
GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound) are powerful — but the evidence is clear: they work best paired with structured nutritional and behavioral support. This 12-week group program maximizes the benefits of GLP-1 therapy, protects lean muscle mass, improves metabolic flexibility, and builds the dietary habits that sustain results long after pharmacotherapy ends. Led by Dr. Druz and the HHC clinical team — medical supervision, registered-nutritionist coaching, and functional-medicine nursing support, in a cohort that combines accountability with clinical rigor.
Who this program is for
- Patients currently on GLP-1 agonist therapy (semaglutide/Wegovy, tirzepatide/Zepbound)
- Patients preparing to start or considering GLP-1 therapy
- Patients wishing to taper off GLP-1 agonist medications, especially with side-effects
- Patients with metabolic syndrome, obesity, prediabetes, or cardiovascular risk factors
- Patients wishing to establish a strong nutritional and lifestyle foundation alongside or after pharmacotherapy
What you get in 12 weeks
Program tools & devices
Lumen Device
Measures respiratory exchange ratio to assess metabolic flexibility and fuel usage (fat vs. carbohydrate). Used daily to guide dietary timing.
Smart Scale
Weekly weigh-ins under consistent morning conditions to track body-weight trends throughout the 12 weeks.
Symptom & Side-Effect Log
Tracks GLP-1 tolerability, hydration, energy, and appetite weekly throughout the program.
Continuous Glucose Monitor (CGM)
Optional — recommended for prediabetes or metabolic syndrome for real-time feedback on dietary choices.
12-week module summary
Expected outcomes
- Clinically meaningful weight loss (targeting ≥10% total body weight)
- Reduction in visceral and pericardial fat
- Improvement in HbA1c, fasting glucose, and lipid profile
- Improved metabolic flexibility (measurable via Lumen respiratory exchange ratio)
- Preservation of lean muscle mass through protein optimization and resistance training
- Reduction in systemic inflammation
- Improved cardiovascular risk-factor profile, including blood pressure and triglycerides
- Sustainable dietary habits designed to maintain results after pharmacotherapy
This program complements, not replaces, your primary cardiologist, electrophysiologist, or PCP. All significan’t changes in weight, medications, cardiac symptoms, or metabolic markers are communicated to your care team. Patients with cardiac conditions — including atrial fibrillation, heart failure, or history of stroke — are monitored with particular attention to hydration, electrolyte balance, and medication interactions throughout the program.
